InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Evommune, Inc.

EVMN Clue Score66
United States Fiscal year ends December CIK 0002044725
$6.25 -2.50% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $6.25 −69.11% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 6 Nov 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2024Revenue7.0Operating income−70.0Net income−66.8EPS, diluted−45.29Fiscal year 2025Revenue13.0 +85.7%Operating income−81.1Net income−68.9EPS, diluted−11.22
FY2024FY2025
Revenue 7.0 13.0
Growth +85.7%
Operating income −70.0 −81.1
Net income −66.8 −68.9
Growth
EPS, diluted −45.29 −11.22

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2024Operating margin−1,000.2%Net margin−954.4%Free cash flow margin−832.6%Fiscal year 2025Operating margin−623.6%Net margin−529.8%Free cash flow margin−589.8%
FY2024FY2025
Operating margin −1,000.2% −623.6%
Net margin −954.4% −529.8%
Free cash flow margin −832.6% −589.8%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow−58.2Capital expenditure−0.1Free cash flow−58.3Fiscal year 2025Operating cash flow−76.4Capital expenditure−0.2Free cash flow−76.7
FY2024FY2025
Operating cash flow −58.2 −76.4
Capital expenditure −0.1 −0.2
Free cash flow −58.3 −76.7
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash16.3Shareholders’ equity−144.2Fiscal year 2025Cash44.1Shareholders’ equity205.6
FY2024FY2025
Cash 16.3 44.1
Shareholders’ equity −144.2 205.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
7.0 13.0
Growth +85.7%
64.2 74.0
12.8 20.0
−70.0 −81.1
Growth
−68.3 −68.9
0.0 0.0
−66.8 −68.9
Growth
Per share
−45.29 −11.22
−45.29 −11.22
Growth
1.5 6.1
1.5 6.1
Growth +306.9%

† The diluted share count jumps at 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 2 years on file.